Abstract
Introduction Several studies characterized COVID-19 patients and revealed the factors associated with COVID-19 mortality and severity. However, few studies were conducted in the Middle East, hence we decided to conduct this study to characterize COVID-19 patients, identify the factors associated with COVID-19 mortality and severity and to compare the patients’ outcomes in the two waves of the pandemic.
Method We conducted a retrospective single center cohort study among COVID-19 patients admitted to our hospital. The primary outcomes were COVID-19 related death, ICU admission and invasive intubation. Whereas, the secondary outcome was the length of hospital stay. In addition, the patients were divided into two cohorts to represent the two waves of the pandemic, to compare between them based on the outcomes.
Results The total number of COVID-19 patients included in our study was 745. The overall rates of COVID-19 related mortality, ICU admission and invasive intubation were 23.0%, 28.3% and 10.8%, respectively. CKD, troponin, LDH and O2 saturation <90% were significant predictors for mortality. Moreover, the significant predictors for ICU admission were HF and remdesivir use. Whereas, O2 saturation<90% and GI symptoms were the only significant predictors for invasive intubation. Additionally, the second wave had significantly higher rates of ICU admission compared to the first one.
Conclusion Our study showed that several factors predicted COVID-19 mortality, ICU admission and invasive intubation. Additionally, our study revealed that the second wave of the pandemic had significantly higher rates of ICU admission but not mortality or invasive intubation compared to the first wave.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
The author(s) received no specific funding for this work.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Not Applicable
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Given the retrospective nature of the study, informed consent was not required. The study protocol was approved by the Institutional Review Board at JUH.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Not Applicable
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Not Applicable
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Not Applicable
Data Availability
The data associated with this manuscript are available in the Supplementary Material
